Doctors at Intermountain Health said Monday they were introducing a “cutting-edge” therapy they hoped would make a difference for patients with advanced melanoma skin cancer.
Tumor-infiltrating lymphocyte (TIL) therapy is used to treat melanoma where the cancer cannot be surgically removed, or where it has spread.
Dr. Caroline Nebhan, Intermountain Health medical oncologist, said the therapy featuring the new medicine AMTAGVI is a potential difference-maker for those with unresponsive melanoma.
READ: https://ksltv.com/?p=771234
Socials for KSL TV:
https://twitter.com/KSL5TV
https://www.facebook.com/ksltv
https://www.instagram.com/kslnews/
Socials for KSL NewsRadio:
https://twitter.com/kslnewsradio
https://www.facebook.com/KSLNewsradio/
https://www.instagram.com/ksl_newsradio/
Tumor-infiltrating lymphocyte (TIL) therapy is used to treat melanoma where the cancer cannot be surgically removed, or where it has spread.
Dr. Caroline Nebhan, Intermountain Health medical oncologist, said the therapy featuring the new medicine AMTAGVI is a potential difference-maker for those with unresponsive melanoma.
READ: https://ksltv.com/?p=771234
Socials for KSL TV:
https://twitter.com/KSL5TV
https://www.facebook.com/ksltv
https://www.instagram.com/kslnews/
Socials for KSL NewsRadio:
https://twitter.com/kslnewsradio
https://www.facebook.com/KSLNewsradio/
https://www.instagram.com/ksl_newsradio/
- Категория
- Онкодерматология

Комментариев нет.